Cidara Therapeutics ^{Priced, Nasdaq: CDTX}

We are a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. Our initial proprietary product candidates are formulations of our novel compound, CD101, for the treatment of serious fungal infections. CD101 is an echinocandin—a proven class of antifungals. Our first product candidate is CD101 intravenous, formerly biafungin, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. Our second product candidate, CD101 topical, formerly topifungin, is a topical formulation of CD101 for the treatment of vulvovaginal candidiasis, a prevalent mucosal infection. CD101 topical is the first topical application of the echinocandin class of antifungals. In addition, we have developed a proprietary immunotherapy technology platform, Cloudbreak, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. We are developing our first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis, an infection caused by the fungal pathogen, Aspergillus. We are also evaluating additional opportunities to expand our Cloudbreak immunotherapy platform to other areas of infectious disease.